- Home
- IMUX vs COYA Comparison
IMUX vs COYA Comparison
Compare IMUX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- COYA
- Stock Information
- Founded
- IMUX 2016
- COYA 2020
- Country
- IMUX United States
- COYA United States
- Employees
- IMUX N/A
- COYA N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- COYA Health Care
- Exchange
- IMUX Nasdaq
- COYA Nasdaq
- Market Cap
- IMUX 86.3M
- COYA 98.5M
- IPO Year
- IMUX N/A
- COYA 2022
- Fundamental
- Price
- IMUX $1.27
- COYA $6.41
- Analyst Decision
- IMUX Strong Buy
- COYA Strong Buy
- Analyst Count
- IMUX 6
- COYA 4
- Target Price
- IMUX $12.67
- COYA $16.25
- AVG Volume (30 Days)
- IMUX 795.3K
- COYA 93.4K
- Earning Date
- IMUX 03-04-2025
- COYA 03-18-2025
- Dividend Yield
- IMUX N/A
- COYA N/A
- EPS Growth
- IMUX N/A
- COYA N/A
- EPS
- IMUX N/A
- COYA N/A
- Revenue
- IMUX N/A
- COYA $9,554,315.00
- Revenue This Year
- IMUX N/A
- COYA N/A
- Revenue Next Year
- IMUX N/A
- COYA $56.22
- P/E Ratio
- IMUX N/A
- COYA N/A
- Revenue Growth
- IMUX N/A
- COYA N/A
- 52 Week Low
- IMUX $0.92
- COYA $4.75
- 52 Week High
- IMUX $2.11
- COYA $10.69
- Technical
- Relative Strength Index (RSI)
- IMUX 72.48
- COYA 52.07
- Support Level
- IMUX $0.92
- COYA $5.85
- Resistance Level
- IMUX $1.15
- COYA $7.25
- Average True Range (ATR)
- IMUX 0.07
- COYA 0.51
- MACD
- IMUX 0.03
- COYA -0.04
- Stochastic Oscillator
- IMUX 74.47
- COYA 32.94
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.